BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare PartnershipProof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone MarketsAugust 12, 2025 8:30 AM EDT | Source: BioMark Diagnostics, Inc.Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today ...

Core Points - BD has received FDA 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test for detecting COVID-19 antigens in symptomatic individuals within approximately 15 minutes [1][2] - The BD Veritor™ System has been available under Emergency Use Authorization since September 2020, and the new clearance will replace the EUA version starting in early fall 2025 [3] - The system is designed for use in CLIA-waived environments and provides results from nasal swab specimens within six days of symptom onset, enhancing timely clinical decision-making [4] Company Overview - BD is one of the largest global medical technology companies, focusing on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and is committed to enhancing the safety and efficiency of healthcare delivery processes [6] - BD collaborates with organizations worldwide to address significant global health challenges, aiming to improve outcomes, lower costs, and expand healthcare access [6]